Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza Split Vaccine (Zhejiang Tianyuan Biopharmaceuticals)
- Development stage
- Approved
- Lead developer
- Tianyuan Bio-Pharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Influenza Split Vaccine developed by Zhejiang Tianyuan Biopharmaceuticals is an inactivated, split-virion vaccine indicated for the prevention of influenza. It is produced by treating inactivated influenza viruses with detergents to disrupt the viral envelope, resulting in a 'split' vaccine that contains purified surface antigens, primarily hemagglutinin (HA) and neuraminidase (NA). This modality is designed to induce protective antibody responses while maintaining a favorable safety profile compared to whole-virus vaccines. The product is approved in China and available in 0.25ml and 0.5ml formulations, targeting both pediatric and adult populations.
- Other names
- 流感病毒裂解疫苗Influenza Virus Split VaccineInfluenza Split Vaccine (0.25ml)Influenza Split Vaccine (0.5ml)
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on Influenza Split Vaccine (Zhejiang Tianyuan Biopharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza Split Vaccine (Zhejiang Tianyuan Biopharmaceuticals).